Literature DB >> 27760452

[Chronic thromboembolic pulmonary hypertension: Recommendations of the Cologne Consensus Conference 2016].

H Wilkens, S Konstantinides, I Lang, A C Bunck, M Gerges, F Gerhardt, A Grgic, C Grohé, S Guth, M Held, J Hinrichs, M M Hoeper, W Klepetko, T Kramm, U Krüger, M Lankeit, B C Meyer, K M Olsson, H-J Schäfers, M Schmidt, H J Seyfarth, S Ulrich, C B Wiedenroth, E Mayer.   

Abstract

The 2015 European Guidelines on Pulmonary Hypertension did not cover only pulmonary arterial hypertension (PAH), but also other significant subgroups of pulmonary hypertension (PH). In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. Several working groups were initiated, one of which was dedicated to the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (CTEPH). In every patient with PH of unknown cause CTEPH should be excluded. The primary treatment option is surgical pulmonary endarterectomy (PEA) in a specialized multidisciplinary CTEPH center. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. For balloon pulmonary angioplasty (BPA), there is currently only limited experience. This option - as PEA - is reserved to specialized centers with expertise for this treatment method. In addition, a brief overview is given on pulmonary artery sarcoma, since its surgical treatment is often analogous to PEA. The recommendations of this working group are summarized in the present paper. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27760452     DOI: 10.1055/s-0042-114529

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  7 in total

Review 1.  [Medicinal treatment of tricuspid valve regurgitation].

Authors:  M Lankeit; K Keller; C Tschöpe; B Pieske
Journal:  Herz       Date:  2017-11       Impact factor: 1.443

2.  [Heart or lung? : Diagnostics and management of unclear exertional dyspnea].

Authors:  H Wilkens; M Held
Journal:  Herz       Date:  2018-09       Impact factor: 1.443

3.  Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease.

Authors:  Christoph B Wiedenroth; Karen M Olsson; Stefan Guth; Andreas Breithecker; Moritz Haas; Jan-Christopher Kamp; Jan Fuge; Jan B Hinrichs; Fritz Roller; Christian W Hamm; Eckhard Mayer; Hossein A Ghofrani; Bernhard C Meyer; Christoph Liebetrau
Journal:  Pulm Circ       Date:  2017-12-28       Impact factor: 3.017

4.  Childhood Maltreatment, Mental Well-Being, and Healthy Lifestyle in Patients With Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Nicole Lepsy; Madelaine-Rachel Dering; Jan Fuge; Tanja Meltendorf; Marius M Hoeper; Ivo Heitland; Jan C Kamp; Da-Hee Park; Manuel J Richter; Henning Gall; Hossein A Ghofrani; Dietmar Ellermeier; Hans-Dieter Kulla; Karen M Olsson; Kai G Kahl
Journal:  Front Psychiatry       Date:  2022-02-24       Impact factor: 4.157

5.  Dynamics of high-sensitivity cardiac troponin T during therapy with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.

Authors:  Steffen D Kriechbaum; Christoph B Wiedenroth; Till Keller; Jan Sebastian Wolter; Ruth Ajnwojner; Karina Peters; Moritz A Haas; Fritz C Roller; Andreas Breithecker; Andreas J Rieth; Stefan Guth; Andreas Rolf; Dirk Bandorski; Christian W Hamm; Eckhard Mayer; Christoph Liebetrau
Journal:  PLoS One       Date:  2018-09-25       Impact factor: 3.240

6.  A case report of primary pulmonary artery intimal sarcoma.

Authors:  Xiaofang Bai; Litao Ruan
Journal:  Eur J Med Res       Date:  2021-08-09       Impact factor: 2.175

7.  Additional treatment prolonged survival of pulmonary artery sarcoma after surgical resection.

Authors:  Liwei Xu; Weishan Lu; Jianqiang Li; Changchun Wang
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.